Skyrizi is a prescription drug used to treat certain autoimmune conditions, such as Crohn’s disease, in adults. There are currently no known interactions between Skyrizi and other medications, alcohol ...

Skyrizi (risankizumab-rzaa) is a prescription drug used to treat certain autoimmune conditions, including plaque psoriasis and Crohn’s disease. It works by attaching to specific proteins in your ...

Skyrizi is used to treat autoimmune and inflammatory conditions like Crohn’s disease and plaque psoriasis. It is administered via intravenous injection by a healthcare professional or subcutaneous ...

Skyrizi (risankizumab-rzaa) is a biologic medication doctors prescribe to treat certain autoimmune and inflammatory conditions. Like any medication, it can cause side effects. But is one of Skyrizi’s ...

SKYRIZI ® (risankizumab), an IL-23 inhibitor, received two consecutive positive reimbursement recommendations by Canada’s Drug Agency (CDA-AMC) for inflammatory bowel diseases, initially for Crohn’s ...

Please provide your email address to receive an email when new articles are posted on . Patients receiving maintenance risankizumab 180 mg or 360 mg achieved higher rates of clinical remission vs.

SKYRIZI is the first IL-23 specific inhibitor approved for both moderate to severe ulcerative colitis and moderate to severe Crohn's disease. 1 "We are so grateful for the approval of SKYRIZI for ...

Physicians have delivered a boost to AbbVie’s hopes of turning Skyrizi into a $17-billion-a-year drug. The 101 gastroenterologists polled by Spherix Global Insights talked up Skyrizi’s promise in ...

AbbVie ABBV delivered encouraging second-quarter 2025 results last week, sending a clear message — it is effectively managing its post-Humira transition. The stronger-than-expected sales of newer ...